Treatment options for Hemophilia A including factors and other biologics.
These guidelines from ASH, ISTH, NHF, and WFH are intended to support patients, clinicians, and healthcare professionals in their decisions affecting the management of VWD.
The FDA has issued guidance to facilitate the availability of coagulation systems during the COVID-19 pandemic.
Investigators noted the importance of improving educational efforts about the safety and efficacy of matched sibling donor HSCT for children with sickle cell disease.
The FDA has accepted for filing and granted Priority Review to narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Treatment options for von Willebrand Disease (VWD).